AN ACT Relating to material changes to the operations and governance structure of participants in the health care marketplace;
SB 5704 creates a new state review and approval process for certain “material change transactions” in Washington’s health care marketplace, including mergers, acquisitions, and contracting affiliations involving hospitals, hospital systems, provider organizations, carriers, and some out-of-state entities. The bill requires advance notice to the Washington State Health Care Authority and the Attorney General, public notice and hearings, and a detailed access, affordability, quality, and equity review before a transaction can proceed. It also authorizes the Attorney General to approve, condition, modify, or disapprove a transaction, and to monitor compliance for at least five years after closing.
The bill is designed to supplement existing antitrust and consumer-protection laws rather than replace them. It gives the Attorney General and the Health Care Authority broad information-gathering authority, allows fees to cover implementation costs, and establishes penalties, injunctions, and other enforcement tools for noncompliance. It also requires post-transaction reporting and ongoing oversight to ensure that affected communities retain access to care and that the transaction does not reduce staffing, hospital privileges, or the availability of essential services.
SB 5704 would add a new chapter to Washington law governing health care consolidation and governance changes, expanding state oversight of health care mergers and related transactions. It would amend multiple RCW provisions to define key terms, establish notice and review procedures, create public hearing requirements, authorize confidentiality protections for submitted materials, and provide civil penalties and enforcement authority. The bill would affect hospitals, hospital systems, provider organizations, carriers, insurance holding companies, and certain out-of-state entities doing business with Washington patients, while also creating obligations for successor entities after a transaction closes.
The bill’s stated purpose and structure reflect a strong policy preference for preserving competition, affordability, access, and equity in health care. The legislative findings emphasize concerns about COVID-era inequities, rising prices, reduced competition, and harm to rural and marginalized communities, suggesting generally supportive sentiment toward stronger oversight. Because no committee transcripts or recorded votes were provided, there is no direct evidence of floor or committee opposition or support beyond the bill text itself.
The main points of contention implied by the bill are the scope of state oversight, the breadth of information required from parties, and the Attorney General’s authority to approve, condition, or block transactions. Health care entities may view the bill as imposing significant procedural burdens, public disclosure obligations, and long-term compliance monitoring, while supporters would likely argue those tools are necessary to prevent anti-competitive consolidation and protect access to care. The bill also appears to draw a distinction between general health care transactions and those involving safety-net providers or rural clinics, which may raise questions about exemptions, thresholds, and how the review standards are applied in practice.